Modality
Peptide
MOA
CD3xCD20
Target
BCMA
Pathway
Notch
FLHCCALL
Development Pipeline
Preclinical
~Oct 2021
→ ~Jan 2023
Phase 1
~Apr 2023
→ ~Jul 2024
Phase 2
Oct 2024
→ May 2025
Phase 2Current
NCT06048909
746 pts·HCC
2024-10→2025-05·Terminated
746 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2010mo agoPh2 Data· HCC
Trial Timeline
Q42025Q2
P2
Termina…
Catalysts
Ph2 Data
2025-05-20 · 10mo ago
HCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06048909 | Phase 2 | HCC | Terminated | 746 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |